Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.04B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.56M
Average 1.66M
Returns on capital
Xeris Biopharma Holdings, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.0%
avg -36.3%
ROIC
8.9%
avg -48.0%
ROA
0.1%
avg -42.5%
Analysis
ROIC is currently the strongest return metric at 8.9% versus its period average of -48.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John Shannon | Chairman & CEO | USD 1.36M | 64 | — | — |
Kevin McCulloch | President & Chief Operating Officer | USD 913.53K | 62 | 1.56M | 0.90% |
Beth Hecht | Chief Legal Officer & Corporate Secretary | USD 817.37K | 62 | 1.09M | 0.63% |
Steven Pieper | Chief Financial Officer | USD 796.18K | 49 | 1.35M | 0.78% |
Anh Nguyen | Chief Medical Officer | USD 653.7K | 51 | — | — |
Joshua Bennett | Vice President of Strategy & Business Development | — | — | — | — |
Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | — | — | — | — |
Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Kendal Korte | Senior Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
35
$5.83M
Net Transaction Value
−$5.83M
Net selling
Most Active
Hecht Beth
13 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | McCulloch Kevin Direct | Sell | $312.2K$312,215.00 |
| Nov 2, 26Nov 2, 2026 | Hecht Beth Direct | Sell | $255.8K$255,827.50 |
| Nov 2, 26Nov 2, 2026 | McCulloch Kevin Direct | Sell | $153.5K$153,487.50 |
| Nov 2, 26Nov 2, 2026 | Pieper Steven Direct | Sell | $51.2K$51,173.50 |
| Oct 1, 26Oct 1, 2026 | Pieper Steven Direct | Sell | $47K$47,036.50 |
| Oct 1, 26Oct 1, 2026 | McCulloch Kevin Direct | Sell | $141.1K$141,120.00 |
| Oct 1, 26Oct 1, 2026 | Hecht Beth Direct | Sell | $156.8K$156,792.06 |
| Sep 28, 26Sep 28, 2026 | McCulloch Kevin Direct | Sell | $250K$250,000.00 |
| Sep 1, 26Sep 1, 2026 | McCulloch Kevin Direct | Sell | $127.3K$127,308.00 |
| Sep 1, 26Sep 1, 2026 | Hecht Beth Direct | Sell | $141.4K$141,434.34 |
1–10 of 35
Summary
Insiders reported 0 buys worth $0.00 and 35 sells worth $5.83M over the last 12 months. That adds up to net selling of $5.83M. Hecht Beth was the most active insider with 13 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +230.7% (5yr)2 analysts |
| Revenue | N/A | N/A | +38.3% | +25.2% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | +230.5% (5yr)3 analysts |
| EBIT | N/A | N/A | N/A | +65.2% (5yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +38.3% over three years. Forward estimates point to EPS at +230.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Xeris Biopharma Holdings, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about XERS's management, answered from reported figures.
Who manages XERS?
Xeris Biopharma Holdings, Inc. (XERS) lists 9 active executives. The top listed executive is Anh Nguyen, Chief Medical Officer.
Are XERS insiders buying or selling?
Recent insider activity shows net buying of $1.37M.
Continue the stock analysis
Jump to another research area for this company.